Editor-in-Chief: Weiping Han
Affiliation: Agency for Science, Technology and Research, A*Star Institute, Singapore
Biography: Weiping Han obtained his Ph.D. in Physiology from Cornell University, and did his postdoctoral work at the University of Pittsburgh and HHMI/UT Southwestern Medical Center in Dallas. In 2005, he moved to Singapore to establish a metabolic medicine research program at A*STAR’s Singapore Bioimaging Consortium, and was promoted to Research Director / Professor in 2013. Currently he is Director of Neurometabolism in Health & Disease at the Institute of Molecular and Cell Biology, A*STAR; with concurrent appointment as Professor in the Department of Biochemistry at National University of Singapore and Program in Cardiovascular and Metabolic Disorders, Duke-NUS Medical School. His research interest is on the biological basis of metabolic diseases and associated complications.
Deputy Editor-in-Chief: Christopher Cooper
Affiliation: University of Huddersfield, UK
Biography: Following my first degree in Biochemistry at the University of Oxford (Merton College), I moved to the Department of Engineering Science and Linacre College to pursue a PhD/DPhil in molecular microbiology and biochemistry. During this time I developed an interest in DNA replication and repair studying thermacidophilic archaea and their DNA polymerases. To pursue my interests in genomics, I then undertook a Masters degree in Bioinformatics at the University of York with a research placement at the University of Uppsala in Sweden. I subsequently moved into eukaryotic molecular biology, working for 3 years at the Nuffield Department of Clinical Laboratory Sciences in Oxford. Here I researched microRNA and cancer-testis antigen expression profiles in human lymphomas, cementing my interests in cancer research. I then undertook two postdoctoral positions at the Structural Genomics Consortium (Oxford), working on high-throughput crystallography and biochemistry of human DNA polymerases and helicases involved in genome integrity, SNF2 family members in remodelling and ETS transcription factors. I continued to research genome integrity factors in cancer during a short postdoc at the Sir William Dunn School of Pathology (Oxford), using structural, biochemical and cell biology approaches to study endonucleases and chromatin remodelling SNF2 ATPases involved in the DNA damage response. During my latter postdoc positions I was appointed as an E.P. Abraham Cephalosporin Junior Research Fellow and a member of the Governing Body at Linacre Collegem and also as a College Lecturer in Biochemistry at the Queen's College. I joined the University of Huddersfield as a Senior Lecturer in Biological Sciences in 2015.
Jane Rosemary Allison
Affiliation: The University of Auckland, New Zealand
Biography: Jane obtained a BSc (Hons) from the University of Canterbury in 2003 and a PhD from Cambridge University in 2008, where she worked with Prof. Chris Dobson. After working as a postdoc with Prof. Wilfred van Gunsteren at ETH Zürich, she returned to New Zealand in 2012 to become a Lecturer at Massey University. She was awarded a Rutherford Discovery Fellowship in 2015, and in 2018, moved to the University of Auckland, where she is an Associate Professor and an Associate Investigator with the Maurice Wilkins Centre for Molecular Biodiscovery and the Biomolecular Interaction Centre at the University of Canterbury.
Affiliation: University of Nottingham, UK
Biography: Edward’s lab is located in the medical school of QMC, University of Nottingham, where they research DNA repair and CRISPR-Cas immunity. Prior to his current position, Ed was a PI as a Wellcome Trust funded Research Career Development Fellow, also at Nottingham, after 5 years as a post-doc working on bacterial DNA repair. His PhD was at the University of London (UCL and QMUL) researching the enzymology of a key step in tetrapyrrole biosynthesis. He has strong collaborative links with several research establishments and universities internationally that allows his laboratory to combine genetics, biochemistry and structural analyses of DNA repair and CRISPR-Cas immunity.
Affiliation: Tata Memorial Centre, India
Biography: Programmed cell death or apoptosis poses an important impediment against cancer. It is evident that effective treatment of cancer needs innovative identification of novel targets from the apoptotic pathway and their therapeutic intervention with greater efficacy and lower toxicity. Dr. Bose’s laboratory is committed toward this objective with her research interest being identification and characterization of targets in the apoptotic pathway so as to design modulators/analogs with desired characteristics using multidisciplinary approach. The group works on the high temperature requirement family of serine proteases (HtrA), the interaction between anti apoptotic c-FLIP and calmodulin as well as caspase-8 and FADD of extrinsic cell death pathway, and the Bcl2 family proteins and their interacting partners. Moreover, the group is now entering into application-based translation research that includes enzymes involved in metabolic reprogramming and their role in altering cancer signaling pathways.
Affiliation: Duke-NUS Medical School, Singapore
Biography: Dr. Valerie Chew graduated from National University Singapore and is current a principal investigator in Translational Immunology Institute (TII) and an assistant professor in Duke-NUS Medical School, Singapore. Dr Chew’s research focuses primarily on understanding the complexity and diversity of the immune context of the tumor microenvironment and its influence on clinical outcome or response to therapy in patients with hepatocellular carcinoma (HCC). Her current work involves high- and multi-dimensional immunophenotyping and immunomonitoring of HCC microenvironment with cutting edge multiplex and single-cell technologies such as Time of Flight Mass Cytometry (CyTOF) and next-generation sequencing (NGS). This powerful approach allows holistic profiling of immune landscapes and the identification of clinically relevant immune subsets or biomarkers predictive of tumour progression and response to therapy. Her work has gained recognition with multiple grant awards and high impact publications.
Affiliation: Senior Manager, Analytical Development ad MilliporeSigma/Merck KGaA; Visiting Professor at University of Sao Paulo, Brazil
Biography: Ricardo G. Correa, PhD, is a pharmacist with over 20 years of scientific experience in biochemistry and molecular biology, and previous industrial experience in the development of analytical methods. Dr Correa has a broad international scientific experience, working at well-recognized institutions like The Salk Institute (USA), University College London (UK) and Universidade de Sao Paulo (Brazil). Dr Correa has 15 years of research experience in cellular signalling pathways involving inflammation, tumorigenesis and immune response. During his PhD, Dr Correa was nominated the first researcher to patent a novel human gene as potential tumour marker in Brazil. During his postdoctoral training, Dr Correa characterized the role of NF-kappaB in the zebrafish model and how this pathway impacts proliferative processes in vertebrates. After his post-doc, Dr Correa was Assistant Professor at the University of Sao Paulo (USP) and the Pontificia Universidade Catolica (PUC) in Brazil. Later, Dr Correa moved to La Jolla (California, USA) to work at the SBP Medical Discovery Institute (SBMRI), and currently serves as Senior Manager, Analytical Development, at MilliporeSigma/Merck KGaA as well as being a Visiting Professor at University of Sao Paulo, Brazil. His work has mainly focused on gene therapy, innate immunity and cancer progression.
Affiliation: Université de Sherbrooke, Canada
Biography: Jean-Bernard Denault is a professor at the Université de Sherbrooke, Québec, Canada, with a Ph.D. degree in Pharmacology. His research interests cover the mechanisms of regulation, activation, and activity of proteolytic enzymes, more specifically that of caspases during apoptosis. Dr. Denault's laboratory is interested in caspase biology with emphasis on their roles in cancer. His projects take advantage of protein engineering, enzymological characterization, gene manipulation, cancer cell models, structural biology, and other approaches to understand how caspases work and how these results can potentially lead to the development of new strategies to modulate their activity.
Affiliation: RWTH Aachen University, Germany
Biography: Karla obtained a BSc from the University of Maastricht, followed by an MSc from the University of Amsterdam with a major in oncology. For her MSc she pursued a research project investigating the role of ubiquitination in the Notch pathway at the Netherlands Cancer Institute. Subsequently, she obtained her PhD from RWTH Aachen University in biochemistry for work on the ADP-ribosyltransferase PARP10. Supported by an EMBO Fellowship, she performed postdoctoral work to study the enzymes MacroD1, MacroD2 and TARG1 at the Sir William Dunn School of Pathology in Oxford. Following a maternity break, Karla then returned to RWTH Aachen University to start her own research group in the Department of Biochemistry and Molecular Biology. In contrast to the well-studied PARP1, several other enzymes of the PARP family are poorly characterised, as are the enzymes reversing ADP-ribosylation. We are interested in defining the function of these transferases and hydrolases in normal physiology as well as in pathologies such as cancer.
Affiliation: OxStem, UK
Biography: Lorna’s experience spans 15 years across biotech and academic sectors in the cardiovascular field. She joined OxStem, a regenerative medicine company, in 2017 and moved to the executive team September 2019. She also holds a visiting scientist position at Oxford University. Lorna is experienced in managing academic-industry partnerships, with strong expertise in cardiovascular cell biology and drug discovery. Lorna previously held a Research fellow and project manager position at the Duke-National University of Singapore Medical School, and led a team at Imperial College London that discovered a cardioprotective small molecule. She has previously held postdoctoral positions in vascular biology at UCL, Reading and Cardiff Universities and worked in the biotechnology sector developing complement-based therapeutics.
Nicola K. Gray
Affiliation: University of Edinburgh, UK
Biography: To be provided
Subash Chandra Gupta
Affiliation: Institute of Science, Banaras Hindu University, India
Biography: Dr. Subash Gupta is an Assistant professor at Department of Biochemistry, Institute of Science, Banaras Hindu University (BHU), India. His current research is focused on uncovering the mechanism by which acidic micro-environment promote cancer growth. His laboratory is also working on cancer chemoprevention and other projects to understand the role of cancer stem cells, exosomal microRNAs and long non-coding RNAs in regulating tumor development. He has been honored with prestigious national and international awards. Currently he is an editorial board member on several scientific journals and an active reviewer on more than 60 journals.
Affiliation: The University of Sydney, Australia
Biography: Michael is a Senior Research Fellow in the Faculty of Medicine and Health at the University of Sydney, Australia. He obtained a BSc (Bioinformatics) with 1st Class Honours from the University of Sydney, and received his PhD in the Department of Pathology, University of Sydney. Since 2013, Michael established a research group that focuses on the elucidation of molecular mechanisms in the pathogenesis of human iron and mitochondrial disorders, with a particular focus on the neurodegenerative and cardio-degenerative disorder, Friedreich’s ataxia, and the regulation of the systematic iron hormone, hepcidin. Michael’s research spans basic science to translational research that utilizes multidisciplinary approaches including bioinformatics, biostatistics, biochemistry, molecular biology, animal genetics and medical science. Michael’s work has been recognized by a collection of prestigious National and International Awards, including Society of Free Radical Research International Young Investigator Award, Rebecca L Cooper Medal and Prize, Sydney Medical School Dean’s Prize, Peter Bancroft Prize, etc. Finally, Michael has been invited to act as grant review panellist for National and International agencies, chaired International conference sessions and served on multiple Editorial Boards.
Affiliation: Beijing Children's Hospital, China
Biography: Dr. Wei Li obtained his Ph.D. degree in Medical Genetics in 1997 and received his postdoctoral training from 1999-2004 at Roswell Park Cancer Institute, Buffalo, New York, where he got his M.S. degree of Bioinformatics in 2004. Dr. Li's own laboratory was founded in 2004 at the Institute of Genetics and Developmental Biology, Chinese Academy of Sciences. In 2015, Dr. Li joined Beijing Children's Hospital, Capital Medical University. Dr. Li's lab is mainly focused on the field of Lysosomal Trafficking, to study the molecular and cellular mechanisms of lysosomal trafficking pathways involved in the biogenesis of lysosome-related organelles and related disorders. Dr. Li's other interest is to translate his research to clinical diagnosis and intervention of inherited diseases by using high-throughput multi-omics studies to identify the disease causative genes. Dr. Wei Li's lab has three core research groups: medical genetics and genomics, bioinformatics and omics (BigData), molecular and cellular biology.
Amy L. Milton
Affiliation: University of Cambridge, UK
Biography: Dr Amy L Milton is a University Senior Lecturer at the Department of Psychology, University of Cambridge, and the Ferreras-Willetts Fellow in Neuroscience at Downing College, Cambridge. Her research focuses on memory reconsolidation from a basic science perspective and in terms of its potential translation into a novel form of treatment for mental health disorders. She received her MA after specialising in Natural Sciences (Neuroscience) at Newnham College, University of Cambridge, and studied for her PhD in Behavioural Neuroscience at the Department of Experimental Psychology, University of Cambridge. She is the Principal Investigator of the Memories in Neuropsychiatric Disorders (MiND) lab, where her group are using a combination of behavioural, pharmacological, and molecular neurobiological approaches in rodents to understand how maladaptive emotional memories become modifiable, and how they persist in the brain.
Affiliation: University of Sydney, Australia
Biography: Dr Sahni has received his PhD in Medicinal Chemistry from the University of Illinois at Chicago in 2011. Currently, Dr. Sahni is appointed as a Research Fellow at the Northern Clinical School, University of Sydney, where he plays a pivotal leadership role in the Pancreatic Cancer Research Group. His team consists of 2 PhD and 1 Masters students. His research is focused on understanding the role of the autophagic pathway in pancreatic cancer progression and development of anti-cancer therapeutic strategies targeting autophagy. He is also involved in several research projects aimed at identifying biomarkers for pancreatic cancer diagnosis and progression. Throughout his career, he has published 53 journal articles in high quality international journals and has received >7600 citations. He has secured a number of research grants from prestigious granting bodies, such as Cancer Australia, National Breast Cancer Foundation and AMP Foundation.
Affiliation: University of Strathclyde, UK
Biography: Fraser obtained an MSci(Hons) in Chemistry from the University of Strathclyde in 2009, which was followed by a PhD under the supervision of Prof. Colin J. Suckling OBE, at the same institution awarded in 2012. His doctoral studies spanned computational and synthetic medicinal chemistry, and microbiology, focussed on developing Minor Groove Binders as novel anti-infective agents. During this time, Fraser also obtained a BA(Hons) in Mathematics and Statistics, and a BSc(Hons) in Computing with Mathematical Sciences, with the Open University. Following the completion of his doctorate in 2012, Fraser obtained a PGDE in Chemistry and an MEd in Education studies whilst embarking on a short career in Secondary School education in Scotland. In 2014 he returned to the research group of Prof. Colin J. Suckling OBE at the University of Strathclyde to take up a Post-Doctoral position that included project managing the, now commercial, Minor Grove Binder drug discovery project, alongside medicinal chemistry, chemical biology and microbiology investigations. During this time, Fraser also completed an MSc in Teaching and Learning in Higher Education and was employed as an associate lecturer in Mathematics by the Open University. Fraser is currently at the University of Strathclyde as a Chancellor's Fellow in the Department of Pure and Applied Chemistry.
Affiliation: Faculty of Science, Masaryk University, Czech Republic
Biography: Dr. Skoda is an Assistant Professor at the Masaryk University and a Postdoctoral Researcher at the International Clinical Research Center (Brno, Czech Republic). He obtained his PhD (2016) in Molecular & Cellular Biology from the Masaryk University. After a post-doctoral research stay in the Michael Hogarty Laboratory at the Center for Childhood Cancer Research, Children’s Hospital of Philadelphia in 2017, he joined The University of Sydney in 2018 to work on a melanoma project as a Postdoctoral Research Associate in the Discipline of Pathology and Bosch Institute. During this time, he was awarded the Sydney Medical School Early Career Researcher Kickstart Grant. In fall 2019, he then returned to Brno where he currently leads the Cancer Stem Cell Group in the Laboratory of Tumor Biology at the Masaryk University. His research focus comprises various aspects of cancer stem cell biology, especially investigating the role of pluripotency factors in tumorigenesis, targeting mitochondrial functions in cancer stem cells, and understanding the molecular roles of CD133 in cancer cell signaling.
Affiliation: Queensland University of Technology, Brisbane, Australia
Biography: Professor Nathan Subramaniam received his PhD from Purdue University, W. Lafayette, Indiana, USA. He did his postgraduate research at the Department of Biochemistry, University of California at Davis, USA. He then joined the group of Prof Wanjin Hong at the Institute of Molecular and Cell Biology, Singapore, where he completed his postdoctoral training in cell biology and protein trafficking. He is currently Professor in Biomedical Sciences (Molecular Medicine) at the Queensland University of Technology, Brisbane, Australia, and leads the Liver Disease and Iron Disorders Research Group at the Institute of Health and Biomedical Innovation and School of Biomedical Sciences. Professor Subramaniam’s interests lie in the study of liver disease and how the liver regulates iron homeostasis. His research interests include understanding the genetics of iron disorders, cell biology of iron transporters, functional consequences of disease-causing mutations, mechanisms involved in regulating iron homeostasis and the development of liver injury.
Affiliation: National University of Singapore, Singapore
Biography: Dr Tan is an Associate Professor at the Infectious Diseases Translational Research Program, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore. She is also a Joint Senior Principal Investigator at the Institute of Molecular and Cell Biology (IMCB), A*STAR. Dr Tan is a molecular virologist, and her research focuses on hepatitis viruses, influenza viruses as well as newly emerged viruses, like the Crimean-Congo haemorrhagic fever virus, severe acute respiratory syndrome coronavirus (SARS-CoV), which emerged in 2002, and SARS-CoV-2, which emerged in 2019 to cause the COVID-19 pandemic. She is also interested in the development of new methods for the production of proteins, design of immunogenic protein fragments as well as novel carriers that can be used to enhance immune responses.
Affiliation: Institute of Molecular and Cell Biology, A*Star Institute, Singapore
Biography: Vinay Tergaonkar obtained his Ph.D. (2001) through an international cancer society (UICC) fellowship for collaborative research at Tufts University, Boston, USA. He has been a fellow (2001-2004) and a special fellow (2004-present) of the Leukemia and Lymphoma Society of America and conducted his postdoctoral studies at the Salk Institute for Biological Studies, La Jolla, California. He joined the Institute of Molecular and Cell Biology (IMCB), Singapore, in late 2005 as Principal Investigator and became a Senior Principal Investigator in 2010 and Research Director in 2015. He is also a Professor at School of Medicine at National University of Singapore. He serves on Editorial Boards of 1) Science Advances (AAAS), 2) Molecular and Cellular Biology (American Society for Molecular Biology), 3) Biochemical Journal (Portland Press) 4) Critical Reviews in Oncology/Hematology (Elsevier Press), 5) BMC Research Notes (Biomed Central) and 6) Telomeres and Telomerase. Work from his lab has received international recognition including the British council development award (2014), the Premiers’ fellowship from Government of South Australia (2015) and University of Macau Distinguished Professorship (2019).
Georg C. Terstappen
Affiliation: Cambrian Biopharma, NY, USA
Biography: Georg Terstappen is the Executive Vice President of Drug Discovery at Cambrian Biopharma. He has nearly 30 years of experience in big pharma and biotech, holding R&D leadership positions at Bayer, GW/GSK, and Abbott/AbbVie – most recently as Head of Preclinical CNS Drug Development with GSK. Georg was also co-founder and CSO of the CNS drug discovery company Siena Biotech and, more recently, CSO of OxStem (a University of Oxford spin-out focused on regenerative medicine). In addition, Georg has led EU R&D framework organizations as Vice-Chair of the Innovative Medicines Strategy group in the context of EFPIA and IMI. He was also adjunct Professor at several European universities for more than ten years and leader of European-wide research programs funded by the EC. Georg has published 90 scientific articles and is an inventor/coinventor of 15 patents. He has a first-class honours degree in Biology and conducted research at the Max-Planck-Institute in Cologne and the Federal Research Centre Juelich for which he has received a PhD in natural sciences.
Tom Van Agtmael
Affiliation: University of Glasgow
Biography: Following his undergraduate training in Biochemistry at the University of Antwerp (Belgium), Dr. Van Agtmael obtained his PhD in molecular genetics at the Murdoch Childrens Research Institute in Melbourne (Australia). He then moved to the MRC Human Genetics Unit in Edinburgh for his post-doctoral training as an EU Marie Curie Fellow during which he identified the first vertebrate Col4a1 mutations and implicated type IV collagen in eye and kidney disease. Following a CVRI Wellcome Trust Fellowship at the University of Edinburgh, he was awarded a MRC New Investigator Research Grant to investigate the role of collagen IV in vascular biology. He then joined the University of Glasgow as a RCUK Fellow in Human Molecular Genetics where he established his research group within the Institute of Cardiovascular and Medical Sciences.
Affiliation: University of South Australia, Australia
Biography: Rietie is currently the Head of Microbiology in the School of Pharmacy and Medical Sciences at the University of South Australia. Her research focuses on antimicrobial resistance in pathogenic microbes which is one of the most serious threats in healthcare today. Her group works on projects aimed at detecting antimicrobial resistance in clinical and environmental settings as well as understanding the factors that drive the rapid dissemination of antibiotic resistant organisms. She is also heading an antimicrobial drug discovery program aimed at finding new therapeutics against drug resistant pathogens. Rietie obtained her BSc(Hons) and Master’s degrees with distinction from the University of the Free State in South Africa before securing a scholarship to do a PhD in the UK. After completing her PhD at the University of Leeds in the beautiful Yorkshire Dales, she moved to Cambridge, where she spent twelve years doing research on multidrug transporters, first as a post-doc and later running her own research group as a Royal Society Dorothy Hodgkin Fellow in the Department of Pharmacology. Not content with moving continents once in a lifetime, she left the ancient buildings and immaculate college lawns of Cambridge for sun and sea in Australia after sixteen years in the UK.
Qiong Annabel Wang
Affiliation: City of Hope National Medical Center
Biography: Qiong Annabel Wang, Ph.D., is an Assistant Professor at the Arthur Riggs Diabetes and Metabolism Research Institute, City of Hope National Medical Center. Dr. Wang’s laboratory focuses on the physiological characterization of adipose tissue remodeling, plasticity, and heterogeneity. They hypothesize that adipose tissue remodeling, both at the cellular and molecular level, is not only essential for normal adipose tissue development & function, but also critical for the pathogenesis of adult & age-related obesity and their related metabolic disorders, as well as postpartum breast cancer formation. Moreover, Dr. Wang’s team aims to determine if manipulating adipose tissue remodeling would prevent or treat metabolic disorders and cancer.
Affiliation: Agency for Science, Technology and Research, A*Star Institute, Singapore
Biography: Caroline Wee received her Bachelor’s degree in Biological Sciences and Psychology from Cornell University, and her PhD in Neurobiology from Harvard University (2016), under the supervision of Professor Florian Engert. After a brief post-doctoral stint in her PhD lab, she returned to Singapore to conduct independent research in 2018 and was promoted to Principal Investigator in 2021. Her current research focuses on leveraging the larval zebrafish model to develop a holistic understanding of the gut-brain signaling pathways governing dietary decisions and other behaviors such as stress or anxiety.
Affiliation: Yale University
Biography: Dr. Min Wu is an associate professor at the Department of Cell Biology at Yale University. Prior to joining Yale, she was an assistant professor at the National University of Singapore, and a principal investigator of the Mechanobiology Institute. She received her undergraduate degree from Peking University, Ph.D at Cornell University, and post-doctoral training at Yale University. The Wu lab studies single cell oscillations and travelling waves, membrane curvature, and cell size homeostasis.
Affiliation: Oklahoma State University, USA
Biography: Dr. Ming Yang is a plant cell and molecular biologist. His major contributions are in the areas of stomatal development, meiotic cell cycle progression, and cell morphogenesis in plants. He has investigated a number of Arabidopsis mutants that exhibit interesting phenotypes in the mentioned areas. His research emphasis is on detecting the effects of individual and combined mutations on cell morphology to gain insights into the molecular mechanisms. Stemming from his experimental work, Dr. Yang has also conducted theoretical investigations into the physical basis of biological rhythms; he proposed that slow diffusion of biomolecules could lead to short pauses in biochemical reactions, which in turn, produce long biological oscillations in a negative feedback loop. Dr. Yang’s group is currently investigating the functions of novel leucine-rich repeat receptor-like kinases in epidermal cell formation and proteins in meiotic checkpoint network in Arabidopsis. Dr. Yang also continues his theoretical work on various biological processes.
Affiliation: Capital Medical University, China
Biography: Chen Zhang obtained his bachelor’s degree in biology from the University of Science and Technology of China and his Ph.D. from the Institute of Neuroscience, Chinese Academy of Sciences. He conducted his postdoctoral work in Prof. Thomas C. Südhof’s laboratory from 2004 to 2010. Dr. Zhang joined Peking University as a principal investigator in neuroscience in 2010, and joined the PKU-IDG/McGovern Institute for Brain Research in 2013. In 2018, He became the Dean of the School of Basic Medical Sciences at Capital Medical University. His research interest is in the molecular basis of neural connection (synapse) formation, primarily focusing on the synaptic cleft's protein composition.